SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kok ET, Schouten BW, Bohnen AM, Groeneveld FPMW, Thomas S, Bosch JLHR. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen study. J Urol 2009; 181: 7106.
  • 2
    Fowke JH, Murff HJ, Signorello LB, Lund L, Blot WJ. Race and socioeconomic status are independently associated with benign prostatic hyperplasia. J Urol 2008; 180: 20916.
  • 3
    Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005; 173: 204853.
  • 4
    Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29: 1725.
  • 5
    Michel MC. The forefront of novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: α-blockers in the treatment of male voiding dysfunction – How do they work and why do they differ in tolerability? J Pharmacol Sci 2010; 112: 1517.
  • 6
    Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 113.
  • 7
    Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008; 62: 154759.
  • 8
    Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol 1998; 160: 78491.
  • 9
    Michel MC, Bressel H-U, Goepel M, Rübben H. A 6-months large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001; 51: 60914.
  • 10
    Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 73042.
  • 11
    Franco-Salinas G, de la Rosette JJMCH, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral-controlled absorption system formulations. Clin Pharmacokin 2010; 49: 17788.
  • 12
    Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld K-H, Staab A, Schäfer H-G, Ieiri I, Higuchi S. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol 2010; 70: 88101.
  • 13
    Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K, Ward J. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 1996; 26: 63745.
  • 14
    Kamimura H, Oishi S, Matsushima H, Watanabe T, Higuchi S, Hall M, Wood SG, Chasseaud LF. Identification of cytochrome P450 isozymes involved in metabolism of the α1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998; 28: 90922.
  • 15
    Taguchi K, Saitoh M, Sato S, Asano M, Michel MC. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther 1997; 280: 15.
  • 16
    Miyazawa Y, Forrest A, Schentag JJ, Kamimura H, Swarz H, Ito Y. Effect of concomitant administration of cimetidine hydrochloride on the pharmacokinetic and safety profile of tamsulosin hydrochloride 0.4 mg in healthy subjects. Curr Ther Res 2002; 63: 1526.
  • 17
    Bertelsen KM, Vankatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 28993.
  • 18
    Troost J, Tatami S, Tsuda Y, Mattheus M, Mehlburger L, Michel MC. Effects of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of a single oral dose of tamsulosin. Br J Clin Pharmacol 2010; 70: 305.
  • 19
    Troost J, Tatami S, Tsuda Y, Mattheus M, Mehlburger L, Michel MC. Effects of the CYP2D6 inhibitor paroxetine on the pharmacokinetics of a single oral dose of tamsulosin. Br J Clin Pharmacol 2010; 70: 3056.
  • 20
    Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCASR). Eur Urol Suppl 2005; 4: 1524.
  • 21
    Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AFGVM, Abrams P. Tamsulosin, the first prostate-selective a1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 15567.
  • 22
    Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective a1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 58796.
  • 23
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892900.
  • 24
    Narayan P, Tewari A, Members of United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 17016.
  • 25
    Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl 2005; 4: 914.
  • 26
    Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995; 6: 21928.
  • 27
    Hemeryck A, Lefebvre RA, de Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000; 67: 28391.
  • 28
    Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 4815.
  • 29
    Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 6017.
  • 30
    Lewis LD. Drug-drug interactions: is there an optimal way to study them? Br J Clin Pharmacol 2010; 70: 7813.
  • 31
    van Hoogdalem EJ, Soeishi Y, Matsushima H, Higuchi S. Disposition of the selective α1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997; 86: 115661.
  • 32
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892900.
  • 33
    Narayan P, Tewari A. Members of United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 17016.
  • 34
    de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33: 4818.
  • 35
    de Mey C, Terpstra I. Orthostatic effects of alfuzosin twice daily vs. tamsulosin one daily in the morning. J Urol 2000; 163 (Suppl.): 220.
  • 36
    Michel MC, Korstanje C, Krauwinkel W, Shear M, Davies J, Quartel A. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl 2005; 4: 5360.
  • 37
    Nieminen T, Ylitalo R, Kööbi T, Ylitalo P, Kähönen M. The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. Eur Urol 2005; 47: 3405.